IDIBAPS participates in European Network on antibiotic resistances and hospital infections

This release is also available in Spanish.

The MOSAR project (Mastering hOSpital Antimicrobial Resistance and its spread into the community) is the first European-scale work devoted to the control and study of antimicrobial resistance in hospitals. MOSAR is coordinated by the Institut national de la sant e de la recherche mdicale (INSERM, Christian Brun-Buisson, unit 657 "Pharmaco-epidemiology and assessment of the impact of health products on populations"), and has about 20 public and private laboratories, and more than 50 hospitals in Europe and Israel. IDIBAPS-Hospital Clnic is the only nationwide representative of the network, and has the participation of the group of Dr. Jordi Vila, head of the Bacteriology Unit of Hospital Clnic, and member of the Public health, epidemiology and international health group of IDIBAPS.

The appearance and spread of resistant bacteria is one of the most alarming events of the last fifty years. This problem is aggravated by the slow pace of design of innovative antibiotics during the last 20 years. This phenomenon is most visible in the framework of hospitals, but general population is also affected, since exchanges between both sectors are increasingly rapid and numerous. Research on the transmission dynamics of four types of microorganisms (methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococcus, Acinetobacter spp. and extended-spectrum-lactamase-producing Enterobacter) will allow a design of strategies to control the appearance and spread of these multiresistant microorganisms.

MOSAR will structure the network in a platform of services in order to establish industrial collaborations with the large private institutions of this field. All MOSAR members are highly involved in the fight against bacterial resistances. MOSAR is a 5-year integrated project

Contact: lex Argem
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer

Page: 1 2

Related biology news :

1. Fundacin BBVA and IDIBAPS reassess the intermittent treatment efficiency against malaria
2. Biodesign Institute participates in first-of-its-kind coyote disaster preparedness drill
3. Yale participates in global human genome initiative
4. European Science Foundations Forward Look reaches out beyond the endless frontiers
5. The UAB heads a European research project on proteases and pathological processes
6. Journalists can register now for ECCO 14 -- the European Cancer Conference
7. Climate changes brews trouble for marine life in European Seas, Marine Board-ESF report says
8. Early Europeans unable to stomach milk
9. European launch of International Polar Year 2007-2008
10. European approval of HIV drug darunavir will provide a potent new option with Fuzeon
11. European launch of International Polar Year 2007-2008

Post Your Comments:

(Date:3/27/2020)... ... March 25, 2020 , ... ixlayer, an industry leader in ... to rapidly launch and scale COVID-19 clinical testing. The ixlayer platform, already encompassing ... adapted for COVID-19 specific content and user flows, allowing physicians/health systems, organizations, and ...
(Date:3/20/2020)... FARMINGTON, Conn. (PRWEB) , ... March 20, 2020 ... ... pioneering the development of human embryonic stem cell (ESC) derived mesenchymal stem cells ... as T-MSC) for the treatment of neurological, autoimmune, and rare orphan diseases, today ...
(Date:3/19/2020)... LAUDERDALE, Fla. (PRWEB) , ... March 19, 2020 , ... ... bestowing his talents as host to the informational show "In Depth". The TV program ... people. "In Depth" is shifting gears on a new episode with a dive into ...
Breaking Biology News(10 mins):
(Date:4/1/2020)... LAKE CITY, and LA JOLLA, Calif. (PRWEB) , ... March 31, ... ... characterization tools, and La Jolla Institute for Immunology (LJI), announced today that they will ... days allowing CoVIC to move therapeutic candidates to the clinic as early as this ...
(Date:3/27/2020)... , ... March 26, 2020 , ... iFirst Medical Technologies, ... development of COVID-19 nasal swab test. , "COVID-19 poses a grave danger to public ... iFirst. "We at iFirst are compelled to act. Broad-based testing and on-the-spot results promise ...
(Date:3/13/2020)... Del. (PRWEB) , ... March 12, 2020 , ... ... collaboration with the APC Microbiome Ireland SFI Research Center (APC), a pioneer in ... on the body and play a significant role in human health, based at ...
(Date:3/10/2020)... Tex. (PRWEB) , ... March ... ... a full-service cold chain biopharmaceutical engineering firm, is pleased to announce ... focus is on combination medical device qualification and validation in the biopharmaceutical ...
Breaking Biology Technology:
Cached News: